Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS
Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
Video Player is loading.
This content originally appeared on our sister site, OncLive.
VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels.
OncLive spoke with Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, about the mechanism of action of VB-111 in patients with ovarian cancer.
The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.
Recent Videos
John Brandsema, MD, on the Roadblocks Faced by Gene Therapies for Muscular Dystrophies
David-Alexandre Gros, MD, on Addressing Unmet Needs in End Stage Kidney Disease With Genetically Modified Porcine Kidney Transplant
David Barrett, JD, on ASGCT’s Q4 2024 Landscape Report
Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response
Reena Sharma, MD, on Future Plans for Evaluating FLT201
Nirav Shah, MD, MSHP, on Evaluating Zamto-Cel in R/R DLBCL
Bhagirathbhai R. Dholaria, MD, on Evaluating P-BCMA-ALLO1 in R/R Myeloma
Reena Sharma, MD, on Assessing Spur Therapeutics’ Gene Therapy FLT201 in Gaucher Disease
Mark Hamilton, MD, PhD, on Analyzing PostCAR Myeloid Neoplasms
Barry J Byrne, MD, PhD, on MDA Care Centers and the Future of Gene Therapy in Neuromuscular Disease
